Medscape Pathology and Laboratory Medicine Podcast This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Dazed and Confused About Molecular Data?
Is molecular profiling integral to choice of treatment or simply a source of confusion? Dr. John Marshall speaks to issues that need to be resolved before 'personalized medicine' is practice-ready. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - October 23, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

New ALK Agents: Lung Cancer's 'Second Miracle'?
Drs. D. Ross Camidge and Giorgio Scagliotti highlight the emerging data in ALK-positive lung cancer that will change the playing field in clinical practice. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - October 7, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

TKI Hikes Survival in Recurrent Ovarian Cancer
Cediranib, bevacizumab, and novel antiangiogenic agents continue to improve survival in first-line and recurrent ovarian cancer, as reported by Dr. Stanley Kaye from ECC 2013. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - October 4, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

The 'Darkest Year Ever' for the NIH?
American Psychiatric Association President Dr. Jeffrey Lieberman on how government policies are out of sync with our country ' s medical needs. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - October 3, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

Panitumumab: Casting a Wider Net for Improved Response
Dr. David Kerr reports on a study indicating that widening the search for RAS mutants other than exon 2 can exclude a further 17% of patients with CRC who will not benefit from panitumumab. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - October 1, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

CIGNA Restricts Coverage of Genetic Testing
Dr. Kathy Miller reports on the potential harm that may come as a result of CIGNA ' s new policy that no genetic testing will be covered unless the patient first sees a genetic counselor. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - September 16, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

CIGNA Restricts Coverage of Genetic Testing
Dr. Kathy Miller reports on the potential harm that may come as a result of CIGNA's new policy that no genetic testing will be covered unless the patient first sees a genetic counselor. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - September 16, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

'Do As I Do: Take Aspirin Daily ’
The evidence for the benefits of low-dose aspirin in primary and secondary prevention of colorectal cancer is so compelling that it has convinced CRC specialist Dr. David Kerr to take 100 mg daily. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - August 30, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

Cancer? Not!
What's in a word? Enough to 'set your hair on fire' if the word is cancer, says Dr. George Lundberg, who comments on the importance of not calling a lesion 'cancer' when it is not. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - August 29, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

Can We Identify Risk for Drug Toxicity?
Drawing on recent developments, Dr. David Kerr suggests that DNA technology could identify markers that correlate with the risk of developing serious cancer drug side effects. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - August 26, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

'Would You Sell Your Soul for $10?'
Dr. Bruce Cheson forecasts that the Sunshine Act, requiring physicians to disclose most payment and gifts from industry over $10, will bring showers of misinterpretation and could hinder research. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - August 26, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

New Tool Cracks the 'Old Chestnut' of Tumor Response
Dr. David Kerr discusses time to tumor growth, a metric that outscored all other means of characterizing tumor response rate and correlated with overall survival in patients with colorectal cancer. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - August 19, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts

Mok and Scagliotti: What You Need to Know About Afatinib
A Skype conversation between Drs. Tony Mok and Giorgio Scagliotti details the efficacy and potential toxicities of afatinib, which is newly approved by the FDA for EGFR-positive lung cancer patients. (Source: Medscape Pathology and Laboratory Medicine Podcast)
Source: Medscape Pathology and Laboratory Medicine Podcast - July 12, 2013 Category: Laboratory Medicine Authors: Medscape Source Type: podcasts